Limited (NYSE AMERICAN: VNRX) CEO Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020.
Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first product, the Nu.Q™ Vet Cancer Screening Test, which he says, is on target for a launch this year. Reynolds also provided an update on recent developments and Volition's activities, including new and ongoing clinical trials.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
